Table 3.
LoQ a, ng/mL | RA b, % | SSE c, % | RE d, % | RSDr e, % | LoQ, ng/mL | RA, % | SSE, % | RE, % | RSDr, % | |
---|---|---|---|---|---|---|---|---|---|---|
Compound | Urine | Serum | ||||||||
GLIO f | 1.1 | 97 | 86 | 112 | 22 | 11 | 63 | 104 | 61 | 15 |
OTA g | 0.16 | 69 | 76 | 90 | 17 | 0.16 | 56 | 79 | 71 | 21 |
AFB1 h | 0.03 | 103 | 111 | 93 | 23 | 0.01 | 82 | 92 | 89 | 22 |
AFM1 i | 0.32 | 70 | 71 | 99 | 18 | 0.22 | 52 | 72 | 73 | 19 |
ZEA j | 1.6 | 78 | 82 | 95 | 19 | 1.0 | 50 | 87 | 57 | 19 |
DON k | 1.4 | 66 | 73 | 90 | 10 | 5.0 | 59 | 62 | 97 | 13 |
DOM1 l | 5.0 | 67 | 58 | 115 | 23 | 5.0 | 60 | 54 | 111 | 14 |
FB1 m | 1.1 | 72 | 64 | 112 | 10 | 3.0 | 56 | 85 | 66 | 23 |
a Limit of Quantification; b Apparent recovery; c Signal Suppression/Enhancement; d Recovery for extraction; e Relative Standard Deviation (repeatability); f Gliotoxin; g Ochratoxin A; h Aflatoxin B1; i Aflatoxin M1; j Zearalenone; k Deoxynivalenol; l De-epoxy deoxynivalenol-1; m Fumonisin B1.